Related Experiment Videos
Pulmonary microthrombi during left ventricular assist device implantation
Igor D Gregoric1, Vijay Patel, Rajko Radovancevic
1The Department of Cardiopulmonary Transplantation, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Texas Heart Institute Journal
|August 19, 2005
Summary
Critically ill patients receiving left ventricular assist devices (LVADs) face bleeding risks. A case study highlights a fatal hemorrhage after treating pulmonary embolism with direct tissue plasminogen activator administration.
Area of Science:
- Cardiovascular Surgery
- Critical Care Medicine
- Hematology
Background:
- Patients with critical heart failure often require left ventricular assist devices (LVADs).
- Coagulation profile alterations are common in LVAD patients, leading to significant postoperative bleeding risks.
- Aprotinin is recognized for reducing bleeding in cardiac surgeries and LVAD implantation.
Observation:
- A patient developed severe pulmonary artery hypertension due to thromboembolic occlusion of pulmonary arterioles post-LVAD implantation.
- This complication arose after cardiopulmonary bypass weaning and heparin reversal with protamine.
- Intraoperative direct pulmonary artery administration of tissue plasminogen activator successfully reversed the thrombosis.
Findings:
- Despite successful thrombosis reversal, the patient experienced massive hemorrhage six hours post-procedure.
- This case represents a rare, catastrophic complication following LVAD implantation.
- Direct pulmonary artery application of tissue plasminogen activator in this context is unprecedented.
Implications:
- This case underscores the complex hemostatic challenges in LVAD patients.
- It highlights a potential, albeit high-risk, intervention for acute pulmonary embolism in this population.
- Further research is needed to understand and mitigate bleeding risks associated with advanced cardiac support therapies.